Reduction of weight and left ventricular mass with serotonin uptake inhibition in obese patients with systemic hypertension**

https://doi.org/10.1016/S0002-9149(99)80671-7Get rights and content

Cited by (14)

  • Role of Obesity in Cardiomyopathy and Pulmonary Hypertension

    2009, Clinics in Chest Medicine
    Citation Excerpt :

    The effects of pharmacologic weight loss on the cardiovascular system are not clear, and the mechanism is not well established. There is some reduction in LV mass index after sertraline-related weight loss.88 Rimonabant has been shown to reduce cardiovascular risk, but its effect on the myocardium is not known.89

  • Cardiovascular consequences of obesity and targets for treatment

    2008, Drug Discovery Today: Therapeutic Strategies
    Citation Excerpt :

    Diet plus exercise-induced weight loss also improved LV cavity size and LV mass [74]. Pharmacotherapy with sertraline has also been shown to have beneficial weight-loss-induced effects on LV mass and mass index [75]. LV function, both diastolic and systolic, also may benefit from weight loss in obese patients [64].

  • Cardiac rehabilitation and depression

    2004, American Journal of Cardiology
  • Management of obesity cardiomyopathy

    2001, American Journal of the Medical Sciences
    Citation Excerpt :

    Mean ventricular septal thickness decreased significantly in normotensive but not hypertensive patients. Finally, Jordan et al11 reported significant reductions of mean left ventricular mass and mass index after weight loss associated with sertraline therapy in mildly to moderately obese subjects. These studies suggest that weight loss is capable of producing a decrease in left ventricular mass in morbidly obese patients with left ventricular hypertrophy that is related, at least in part, to improvement in left ventricular loading conditions.

View all citing articles on Scopus
**

In conclusion, if confirmed in larger studies extended over longer time periods, serotonin uptake inhibition, which was associated with significant reductions in weight, arterial pressure, and LV mass indexes, may become a potential adjunctive treatment for patients with obesity hypertension.

*

Dr. Messerli's address is: Department of internal Medicine, Section on Hypertension, Ochsner Clinic, 1514 Jefferson Highway, New Orleans, Louisiana 70121.

View full text